- Enrollment in MEDALIST and BELIEVE Phase 3 studies now expected to be completed in Q2 2017 -
- Acceleron and Celgene to initiate an additional Phase 3 trial in first-line, lower-risk MDS in early 2018 to expand opportunity beyond ongoing MEDALIST study -
"Our pivotal luspatercept studies continue to gain momentum as
enrollment nears completion, and new clinical data support the drug's
expanded development in patient groups in need of more treatment
Updated Phase 3 Clinical Trials Enrollment Guidance
Acceleron and Celgene provided updated guidance on the anticipated completion of patient enrollment for the MEDALIST and BELIEVE Phase 3 studies of luspatercept in MDS and beta-thalassemia, respectively. Based on accelerating rates of patient recruitment, the companies expect to achieve full enrollment of both studies in the second quarter of 2017, versus previous guidance of the second half of 2017.
New Phase 3 Clinical Trial
Acceleron and Celgene also plan to initiate a third Phase 3 trial of
luspatercept. The new Phase 3 trial, expected to be initiated in early
2018, will evaluate luspatercept treatment versus standard-of-care in
the first-line treatment setting for MDS patients. Current first-line,
standard-of-care treatment for lower-risk MDS patients includes
erythropoiesis-stimulating agents (ESAs) and/or regular red blood cell
transfusions. The ongoing MEDALIST Phase 3 trial is evaluating
Luspatercept Data at the Upcoming MDS Symposium
Acceleron and Celgene plan to report updated Phase 2 data on
luspatercept in first-line, lower-risk MDS patients in an oral
presentation at the 14th International Symposium on MDS on
Luspatercept is a modified activin receptor type IIB fusion protein that acts as a ligand trap for members in the Transforming Growth Factor-Beta (TGF-beta) superfamily involved in the late stages of erythropoiesis (red blood cell production). Luspatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation. This mechanism of action is distinct from that of erythropoietin (EPO), which stimulates the proliferation of early-stage erythrocyte precursor cells. Acceleron and Celgene are jointly developing luspatercept as part of a global collaboration. Acceleron and Celgene are enrolling Phase 3 clinical trials that are designed to evaluate the safety and efficacy of luspatercept in patients with myelodysplastic syndromes (the "MEDALIST" study) and in patients with beta-thalassemia (the "BELIEVE" study). For more information, please visit www.clinicaltrials.gov.
Luspatercept is an investigational product that is not approved for use in any country.
Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body's ability to rebuild and repair its own cells and tissues. This approach to drug discovery has generated four therapeutic candidates that are currently in clinical trials. The Company's lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements about the Company's strategy, future plans and prospects, including statements regarding the development of luspatercept, the timeline for clinical development and regulatory approval of the Company's compounds, the expected timing for the reporting of data from ongoing trials, and the structure of the Company's planned or pending clinical trials. The words "anticipate," "appear," "believe," "continue," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks that preclinical testing of the Company's compounds and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that data may not be available when the Company expects it to be, that the Company or its collaboration partner, Celgene, will be unable to successfully complete the clinical development of the Company's compounds, that the development of the Company's compounds will take longer or cost more than planned, that the Company or Celgene may be delayed in initiating, enrolling or completing any clinical trials, that the Company's drug discovery activities may not yield drug candidates for which the Company can commence clinical trials at the rate at which the Company currently anticipates or at all, and that the Company's compounds will not receive regulatory approval or become commercially successful products.
Other risks and uncertainties include those identified under the heading
"Risk Factors" included in the Company's Annual Report on Form 10-K
which was filed with the
Senior Director, Investor Relations and Corporate Communications
News Provided by Acquire Media